GPI 1485
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Impotence
Conditions
Impotence, Prostate Cancer
Trial Timeline
Dec 1, 2003 → —
NCT ID
NCT00090376About GPI 1485
GPI 1485 is a phase 2 stage product being developed by Eisai for Impotence. The current trial status is completed. This product is registered under clinical trial identifier NCT00090376. Target conditions include Impotence, Prostate Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00090376 | Phase 2 | Completed |
| NCT00209508 | Phase 2 | Completed |
Competing Products
20 competing products in Impotence
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tadalafil | Eli Lilly | Approved | 85 |
| tadalafil + sildenafil | Eli Lilly | Approved | 85 |
| tadalafil + placebo + tadalafil + tadalafil + tadalafil + placebo | Eli Lilly | Phase 3 | 77 |
| tadalafil + sildenafil | Eli Lilly | Approved | 85 |
| tadalafil | Eli Lilly | Approved | 85 |
| tadalafil + sildenafil | Eli Lilly | Phase 3 | 77 |
| tadalafil | Eli Lilly | Phase 3 | 77 |
| tadalafil + placebo + tadalafil + tadalafil | Eli Lilly | Phase 3 | 77 |
| tadalafil + Placebo | Eli Lilly | Phase 3 | 77 |
| tadalafil + tadalafil + placebo | Eli Lilly | Phase 3 | 77 |
| tadalafil + tadalafil + placebo | Eli Lilly | Phase 3 | 77 |
| Fluvastatin-sodium | Novartis | Phase 3 | 77 |
| Sildenafil Citrate | Pfizer | Approved | 84 |
| UK0369,003 + Cialis (Tadalafil) | Pfizer | Phase 2 | 51 |
| Viagra (Sildenafil citrate) | Pfizer | Approved | 84 |
| sildenafil citrate | Pfizer | Approved | 84 |
| Placebo + Viagra (sildenafil citrate) | Pfizer | Approved | 84 |
| UK-369,003 | Pfizer | Phase 2 | 51 |
| Viagra (Sildenafil Citrate) 100 mg | Pfizer | Approved | 84 |
| Viagra (Sildenafil citrate) | Pfizer | Approved | 84 |